Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Correction to: FAK-ERK activation in cell/matrix adhesion induced by the loss of apolipoprotein E stimulates the malignant progression of ovarian cancer.

Lai H, Zhao X, Qin Y, Ding Y, Chen R, Li G, Labrie M, Ding Z, Zhou J, Hu J, Ma D, Fang Y, Gao Q.

J Exp Clin Cancer Res. 2019 Oct 15;38(1):415. doi: 10.1186/s13046-019-1422-6.

2.

A randomized pilot study of patients with tandem carotid lesions undergoing thrombectomy.

Poppe AY, Jacquin G, Stapf C, Daneault N, Deschaintre Y, Gioia LC, Odier C, Labrie M, Nehme A, Nico L, Roy D, Weill A, Raymond J.

J Neuroradiol. 2019 Sep 26. pii: S0150-9861(19)30445-6. doi: 10.1016/j.neurad.2019.08.003. [Epub ahead of print]

PMID:
31563589
3.

Proteomics advances for precision therapy in ovarian cancer.

Labrie M, Kendsersky ND, Ma H, Campbell L, Eng J, Chin K, Mills GB.

Expert Rev Proteomics. 2019 Sep 13:1-10. doi: 10.1080/14789450.2019.1666004. [Epub ahead of print]

PMID:
31512530
4.

Cincinnati Prehospital Stroke Scale for EMS Redirection of Large Vessel Occlusion Stroke.

Nehme A, Deschaintre Y, Labrie M, Daneault N, Odier C, Poppe AY, Ross D, Stapf C, Jacquin G, Gioia LC.

Can J Neurol Sci. 2019 Jul 15:1-7. doi: 10.1017/cjn.2019.242. [Epub ahead of print]

PMID:
31303192
5.

Varicella-zoster virus vasculopathy in a multiple sclerosis patient on fingolimod.

Muccilli A, Nehme A, Labrie M, Girard M, Odier C, Poppe AY.

J Neurol Sci. 2019 Aug 15;403:119-121. doi: 10.1016/j.jns.2019.06.025. Epub 2019 Jun 26. No abstract available.

PMID:
31276860
6.

Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options.

Labrie M, Kim TB, Ju Z, Lee S, Zhao W, Fang Y, Lu Y, Chen K, Ramirez P, Frumovitz M, Meyer L, Fleming ND, Sood AK, Coleman RL, Mills GB, Westin SN.

Oncotarget. 2019 May 28;10(37):3533-3546. doi: 10.18632/oncotarget.26947. eCollection 2019 May 28.

7.

Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy.

Fang Y, McGrail DJ, Sun C, Labrie M, Chen X, Zhang D, Ju Z, Vellano CP, Lu Y, Li Y, Jeong KJ, Ding Z, Liang J, Wang SW, Dai H, Lee S, Sahni N, Mercado-Uribe I, Kim TB, Chen K, Lin SY, Peng G, Westin SN, Liu J, O'Connor MJ, Yap TA, Mills GB.

Cancer Cell. 2019 Jun 10;35(6):851-867.e7. doi: 10.1016/j.ccell.2019.05.001.

PMID:
31185210
8.

Lack of Consensus Among Stroke Experts on the Optimal Management of Patients With Acute Tandem Occlusion.

Jacquin G, Poppe AY, Labrie M, Daneault N, Deschaintre Y, Gioia LC, Odier C, Raymond J, Roy D, Weill A, Stapf C.

Stroke. 2019 May;50(5):1254-1256. doi: 10.1161/STROKEAHA.118.023758.

PMID:
30890115
9.

PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness.

Shen J, Zhao W, Ju Z, Wang L, Peng Y, Labrie M, Yap TA, Mills GB, Peng G.

Cancer Res. 2019 Jan 15;79(2):311-319. doi: 10.1158/0008-5472.CAN-18-1003. Epub 2018 Nov 27.

PMID:
30482774
10.

A-to-I RNA Editing Contributes to Proteomic Diversity in Cancer.

Peng X, Xu X, Wang Y, Hawke DH, Yu S, Han L, Zhou Z, Mojumdar K, Jeong KJ, Labrie M, Tsang YH, Zhang M, Lu Y, Hwu P, Scott KL, Liang H, Mills GB.

Cancer Cell. 2018 May 14;33(5):817-828.e7. doi: 10.1016/j.ccell.2018.03.026. Epub 2018 Apr 26.

11.

FAK-ERK activation in cell/matrix adhesion induced by the loss of apolipoprotein E stimulates the malignant progression of ovarian cancer.

Lai H, Zhao X, Qin Y, Ding Y, Chen R, Li G, Labrie M, Ding Z, Zhou J, Hu J, Ma D, Fang Y, Gao Q.

J Exp Clin Cancer Res. 2018 Feb 20;37(1):32. doi: 10.1186/s13046-018-0696-4. Erratum in: J Exp Clin Cancer Res. 2019 Oct 15;38(1):415.

12.

Collaborative and participatory approaches to building community capacity for palliative and end of life care.

LaBrie M.

Ann Palliat Med. 2018 Jan;7(Suppl 1):AB002. doi: 10.21037/apm.2018.s002.

13.

Tissue and plasma levels of galectins in patients with high grade serous ovarian carcinoma as new predictive biomarkers.

Labrie M, De Araujo LOF, Communal L, Mes-Masson AM, St-Pierre Y.

Sci Rep. 2017 Oct 16;7(1):13244. doi: 10.1038/s41598-017-13802-5.

14.

Galectin signatures contribute to the heterogeneity of breast cancer and provide new prognostic information and therapeutic targets.

Grosset AA, Labrie M, Vladoiu MC, Yousef EM, Gaboury L, St-Pierre Y.

Oncotarget. 2016 Apr 5;7(14):18183-203. doi: 10.18632/oncotarget.7784.

15.

Treatment outcomes with telaprevir-based therapy for HIV/hepatitis C coinfected patients are comparable with hepatitis C monoinfected patients.

O'Neil CR, Pang JX, Lee SS, Swain MG, Burak KW, Klein P, Myers RP, Kapler J, Gill MJ, Labrie M, Coffin CS.

Can J Infect Dis Med Microbiol. 2015 Nov-Dec;26(6):293-6. No abstract available.

16.

Design of a peptidic inhibitor that targets the dimer interface of a prototypic galectin.

Vladoiu MC, Labrie M, Létourneau M, Egesborg P, Gagné D, Billard É, Grosset AA, Doucet N, Chatenet D, St-Pierre Y.

Oncotarget. 2015 Dec 1;6(38):40970-80. doi: 10.18632/oncotarget.5403.

17.

A Mutation in the Carbohydrate Recognition Domain Drives a Phenotypic Switch in the Role of Galectin-7 in Prostate Cancer.

Labrie M, Vladoiu M, Leclerc BG, Grosset AA, Gaboury L, Stagg J, St-Pierre Y.

PLoS One. 2015 Jul 13;10(7):e0131307. doi: 10.1371/journal.pone.0131307. eCollection 2015.

18.

Apolipoprotein D Transgenic Mice Develop Hepatic Steatosis through Activation of PPARγ and Fatty Acid Uptake.

Labrie M, Lalonde S, Najyb O, Thiery M, Daneault C, Des Rosiers C, Rassart E, Mounier C.

PLoS One. 2015 Jun 17;10(6):e0130230. doi: 10.1371/journal.pone.0130230. eCollection 2015.

19.

Transcriptional activity of the giant barrel sponge, Xestospongia muta Holobiont: molecular evidence for metabolic interchange.

Fiore CL, Labrie M, Jarett JK, Lesser MP.

Front Microbiol. 2015 Apr 28;6:364. doi: 10.3389/fmicb.2015.00364. eCollection 2015.

20.

OA58 Community capacity development for enhanced hospice palliative care: exploring the value of community engagement.

Whitfield K, LaBrie M.

BMJ Support Palliat Care. 2015 Apr;5 Suppl 1:A18-9. doi: 10.1136/bmjspcare-2015-000906.58.

PMID:
25960480
21.

Cytosolic galectin-7 impairs p53 functions and induces chemoresistance in breast cancer cells.

Grosset AA, Labrie M, Gagné D, Vladoiu MC, Gaboury L, Doucet N, St-Pierre Y.

BMC Cancer. 2014 Nov 3;14:801. doi: 10.1186/1471-2407-14-801.

22.

Expression and functions of galectin-7 in ovarian cancer.

Labrie M, Vladoiu MC, Grosset AA, Gaboury L, St-Pierre Y.

Oncotarget. 2014 Sep 15;5(17):7705-21.

23.

The CCAAT/enhancer-binding protein beta-2 isoform (CEBPβ-2) upregulates galectin-7 expression in human breast cancer cells.

Campion CG, Labrie M, Grosset AA, St-Pierre Y.

PLoS One. 2014 May 2;9(5):e95087. doi: 10.1371/journal.pone.0095087. eCollection 2014.

24.

Intracellular galectins in cancer cells: potential new targets for therapy (Review).

Vladoiu MC, Labrie M, St-Pierre Y.

Int J Oncol. 2014 Apr;44(4):1001-14. doi: 10.3892/ijo.2014.2267. Epub 2014 Jan 21. Review.

25.

Treatment of genotype 2 and genotype 3 hepatitis C virus (HCV) infection in human immunodeficiency virus positive patients.

Brown K, LaBrie M, Coffin CS.

Curr HIV/AIDS Rep. 2013 Dec;10(4):420-7. doi: 10.1007/s11904-013-0186-4. Review.

PMID:
24254131
26.

Expression of galectin-7 is induced in breast cancer cells by mutant p53.

Campion CG, Labrie M, Lavoie G, St-Pierre Y.

PLoS One. 2013 Aug 14;8(8):e72468. doi: 10.1371/journal.pone.0072468. eCollection 2013.

27.

Binding and repressive activities of apolipoprotein E3 and E4 isoforms on the human ApoD promoter.

Levros LC Jr, Labrie M, Charfi C, Rassart E.

Mol Neurobiol. 2013 Dec;48(3):669-80. doi: 10.1007/s12035-013-8456-0. Epub 2013 May 30.

PMID:
23715769
28.

Epigenetic regulation of mmp-9 gene expression.

Labrie M, St-Pierre Y.

Cell Mol Life Sci. 2013 Sep;70(17):3109-24. doi: 10.1007/s00018-012-1214-z. Epub 2012 Nov 27. Review.

PMID:
23184252
29.

Stroke care--more than just saving brain.

Simon J, LaBrie MJ, Coutts SB.

Can J Neurol Sci. 2009 Nov;36(6):671-2. No abstract available.

PMID:
19960741
30.

Development of quality indicators of care for patients undergoing hepatic resection for metastatic colorectal cancer using a Delphi process.

Dixon E, Armstrong C, Maddern G, Sutherland F, Hemming A, Wei A, Sherman M, Moore M, McKay A, Urbach D, Labrie M, Gordon L, Barkun J, Lynn Quan M, Dowden S, Bigam D, Gallinger S.

J Surg Res. 2009 Sep;156(1):32-38.e1. doi: 10.1016/j.jss.2009.03.084. Epub 2009 May 12.

PMID:
19592015
31.

Downregulation of the PI3K/Akt survival pathway in cells with deregulated expression of c-Myc.

Bellmann K, Martel J, Poirier DJ, Labrie MM, Landry J.

Apoptosis. 2006 Aug;11(8):1311-9.

PMID:
16788862
32.

c-Myc potentiates the mitochondrial pathway of apoptosis by acting upstream of apoptosis signal-regulating kinase 1 (Ask1) in the p38 signalling cascade.

Desbiens KM, Deschesnes RG, Labrie MM, Desfossés Y, Lambert H, Landry J, Bellmann K.

Biochem J. 2003 Jun 1;372(Pt 2):631-41.

Supplemental Content

Loading ...
Support Center